WO2007071456B1 - Fluorenes and carbazoles as ligands of the ep2 receptor - Google Patents

Fluorenes and carbazoles as ligands of the ep2 receptor

Info

Publication number
WO2007071456B1
WO2007071456B1 PCT/EP2006/012640 EP2006012640W WO2007071456B1 WO 2007071456 B1 WO2007071456 B1 WO 2007071456B1 EP 2006012640 W EP2006012640 W EP 2006012640W WO 2007071456 B1 WO2007071456 B1 WO 2007071456B1
Authority
WO
WIPO (PCT)
Prior art keywords
carbazol
acetic acid
butoxy
pentyloxy
yloxy
Prior art date
Application number
PCT/EP2006/012640
Other languages
English (en)
French (fr)
Other versions
WO2007071456A1 (en
Inventor
Nico Braeuer
Bernd Buchmann
Christoph Huwe
Bernhard Lindenthal
Gernot Langer
Olaf Peters
Gerd Schubert
Ulrich Bothe
Luisella Toschi
Michaele Peters-Kottig
Original Assignee
Bayer Schering Pharma Ag
Nico Braeuer
Bernd Buchmann
Christoph Huwe
Bernhard Lindenthal
Gernot Langer
Olaf Peters
Gerd Schubert
Ulrich Bothe
Luisella Toschi
Michaele Peters-Kottig
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag, Nico Braeuer, Bernd Buchmann, Christoph Huwe, Bernhard Lindenthal, Gernot Langer, Olaf Peters, Gerd Schubert, Ulrich Bothe, Luisella Toschi, Michaele Peters-Kottig filed Critical Bayer Schering Pharma Ag
Publication of WO2007071456A1 publication Critical patent/WO2007071456A1/en
Publication of WO2007071456B1 publication Critical patent/WO2007071456B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Reproductive Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PCT/EP2006/012640 2005-12-22 2006-12-21 Fluorenes and carbazoles as ligands of the ep2 receptor WO2007071456A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005062741A DE102005062741A1 (de) 2005-12-22 2005-12-22 Fluorene und Carbazole als Liganden des EP2 Rezeptors
DE102005062741.2 2005-12-22

Publications (2)

Publication Number Publication Date
WO2007071456A1 WO2007071456A1 (en) 2007-06-28
WO2007071456B1 true WO2007071456B1 (en) 2007-08-23

Family

ID=37964801

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/012640 WO2007071456A1 (en) 2005-12-22 2006-12-21 Fluorenes and carbazoles as ligands of the ep2 receptor

Country Status (3)

Country Link
US (1) US20070197524A1 (zh-TW)
DE (1) DE102005062741A1 (zh-TW)
WO (1) WO2007071456A1 (zh-TW)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2094273B1 (en) 2006-11-16 2013-03-06 Gemmus Pharma Inc. EP2 and EP4 agonists as agents for the treatment of influenza A viral infection
EP2014663A1 (de) * 2007-07-12 2009-01-14 Bayer Schering Pharma AG Thienopyrimidylamine als Modulatoren des EP2-Rezeptors
EP2149552A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma AG 5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors
EP2149551A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma AG N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors
EP2149554A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma Aktiengesellschaft Indolylamide als Modulatoren des EP2-Rezeptors
US9162980B2 (en) 2009-01-09 2015-10-20 Board Of Regents Of The University Of Texas System Anti-depression compounds
CN102405043B (zh) 2009-01-09 2017-08-22 得克萨斯州大学系统董事会 前神经原性化合物
US8362277B2 (en) 2009-01-09 2013-01-29 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US20120202288A1 (en) 2009-03-19 2012-08-09 Fate Therapeutics, Inc. Compositions comprising cyclic amp enhancers and/or ep ligands, and methods of preparing and using the same
DE102009049662A1 (de) 2009-10-13 2011-04-14 Bayer Schering Pharma Aktiengesellschaft 2,5-Disubstituierte 2H-Indazole als EP2-Rezeptor-Antagonisten
CN103415289B (zh) 2010-07-07 2017-04-12 得克萨斯州大学系统董事会 前神经原性化合物
CN112516167A (zh) 2010-08-12 2021-03-19 菲特治疗公司 改进的造血干细胞和祖细胞疗法
IN2014CN02518A (zh-TW) 2011-09-30 2015-07-31 Bluebird Bio Inc
TW201326154A (zh) 2011-11-28 2013-07-01 拜耳知識產權公司 作為ｅｐ２受體拮抗劑之新穎２ｈ－吲唑
US9452186B2 (en) 2011-12-02 2016-09-27 Fate Therapeutics, Inc. Enhanced stem cell composition
ES2682255T3 (es) 2011-12-02 2018-09-19 Fate Therapeutics, Inc. Métodos mejorados de tratamiento de isquemia
AU2013305591B2 (en) 2012-08-24 2017-04-13 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US9943545B2 (en) 2013-03-15 2018-04-17 Fate Therapeutics, Inc. Stem cell culture media and methods of enhancing cell survival
US10851412B2 (en) 2013-03-15 2020-12-01 Fate Therapeutics, Inc. Cell potency assay for therapeutic potential
WO2015070237A1 (en) 2013-11-11 2015-05-14 Board Of Regents Of The University Of Texas System Neuroprotective chemicals and methods for identifying and using same
WO2015070234A2 (en) 2013-11-11 2015-05-14 Board Of Regents Of The University Of Texas System Neuroprotective compounds and use thereof
EP3770252A1 (en) 2015-01-26 2021-01-27 Fate Therapeutics, Inc. Cells with increased immuno-regulatory properties and methods for their use and manufacture
KR20180033537A (ko) 2015-07-21 2018-04-03 더 칠드런스 메디칼 센터 코포레이션 Pd-l1 발현 조혈 줄기 세포 및 용도
KR20180110112A (ko) 2016-02-12 2018-10-08 블루버드 바이오, 인코포레이티드. Vcn 인핸서 조성물 및 이의 사용 방법
US11326183B2 (en) 2016-02-12 2022-05-10 Bluebird Bio, Inc. VCN enhancer compositions and methods of using the same
WO2019060708A1 (en) 2017-09-22 2019-03-28 The Children's Medical Center Corporation TREATMENT OF TYPE 1 DIABETES AND AUTOIMMUNE DISEASES OR DISORDERS
EP4146797A1 (en) 2020-05-06 2023-03-15 Orchard Therapeutics (Europe) Limited Treatment for neurodegenerative diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5079260A (en) * 1989-06-22 1992-01-07 Nova Pharmaceutical Corporation Method for treating inflammation and compounds and compositions suitable for use therein
IL104043A0 (en) * 1991-12-12 1993-05-13 Scios Nova Inc Fluorenyl derivatives and pharmaceutical compositions containing them
CA2419580A1 (en) * 2000-08-18 2002-02-28 Genentech, Inc. Integrin receptor inhibitors
CA2583622A1 (en) * 2004-10-13 2006-04-27 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension

Also Published As

Publication number Publication date
US20070197524A1 (en) 2007-08-23
DE102005062741A1 (de) 2007-06-28
WO2007071456A1 (en) 2007-06-28

Similar Documents

Publication Publication Date Title
WO2007071456B1 (en) Fluorenes and carbazoles as ligands of the ep2 receptor
US10227315B2 (en) Mitochondrial uncouplers for treatment of metabolic diseases and cancer
RU2001132139A (ru) Имидазохинолины с сульфонамидными или сульфамидным замещением
EP2175861B1 (en) Pharmaceutical combination of naproxen with 13,14-dihydro-15-keto-16,16-difluoro-18-methyl-prostaglandin E1
JP2009526831A5 (zh-TW)
US8673876B2 (en) Pharmaceutical combinations for treatment of specific cancers
US9012509B2 (en) Method of treating non-alcoholic steatohepatitis
JP2010510232A (ja) 眼圧降下剤であるプロスタグランジンプロドラッグ
WO2010040286A1 (zh) 三乙酰基-3-羟基苯基腺苷及其调血脂的用途
JPWO2015129809A1 (ja) 虚血性眼疾患の処置用の医薬組成物
JP2023529834A (ja) コロナウイルス感染症を治療する方法
JP5254007B2 (ja) 置換β−ラクタム及び医薬におけるその使用
US10561649B2 (en) Pharmaceutical combination of opioid and prostaglandin compound
TW201341365A (zh) 作用於多種前列腺素受體從而提供一般抗發炎反應之化合物
CN105777664A (zh) 2-（2-苄亚肼基）噻唑-5-羧酸酯及其制备方法与医药用途
CN106977472A (zh) 苯并异硒唑酮修饰亚硝脲类化合物合成及其应用
CN111943906B (zh) 脒类衍生物、及其制法和药物组合物与用途
CN110498829B (zh) 雷公藤内酯醇衍生物及其制备方法和其药物组合物与用途
AU2010296307B2 (en) Pharmaceutical combination for treating tumor
JPH05255114A (ja) 非定型β−アドレナリン受容体作動薬の医学的用途
JP6152387B2 (ja) Ｉ型およびｉｉ型糖尿病の処置
JP2023505687A (ja) 癌の処置方法
EP3962482A1 (en) Tie-2 activators targeting the schlemm's canal
CA2036039A1 (en) Method for treatment of sleep apneas
WO2024054766A2 (en) Mitochondrial uncouplers for treatment of metabolic diseases and cancer

Legal Events

Date Code Title Description
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase

Ref document number: 06829904

Country of ref document: EP

Kind code of ref document: A1